ScandiDos AB (publ) (SDOS.ST)
SEK 1.64
(-1.2%)
SEK 1.64
(-1.2%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 60.42 Million SEK | -1.82% |
| 2022 | 61.55 Million SEK | 6.7% |
| 2021 | 57.68 Million SEK | -3.84% |
| 2020 | 59.99 Million SEK | 4.75% |
| 2019 | 57.27 Million SEK | 17.3% |
| 2018 | 48.82 Million SEK | -3.45% |
| 2017 | 50.57 Million SEK | 6.67% |
| 2016 | 47.4 Million SEK | 41.2% |
| 2015 | 33.57 Million SEK | 1.98% |
| 2014 | 32.92 Million SEK | -14.93% |
| 2013 | 38.69 Million SEK | -2.85% |
| 2012 | 39.83 Million SEK | 10.71% |
| 2011 | 35.97 Million SEK | 24.35% |
| 2010 | 28.93 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 12.63 Million SEK | -13.84% |
| 2023 Q1 | 11.97 Million SEK | -34.81% |
| 2023 FY | 60.42 Million SEK | -1.82% |
| 2023 Q4 | 14.66 Million SEK | -17.68% |
| 2023 Q3 | 17.81 Million SEK | 7.51% |
| 2023 Q2 | 16.57 Million SEK | 38.38% |
| 2022 Q4 | 18.36 Million SEK | 10.22% |
| 2022 Q1 | 10.82 Million SEK | -34.75% |
| 2022 FY | 61.55 Million SEK | 6.7% |
| 2022 Q2 | 15.69 Million SEK | 44.98% |
| 2022 Q3 | 16.66 Million SEK | 6.19% |
| 2021 Q2 | 13.34 Million SEK | 11.78% |
| 2021 Q4 | 16.58 Million SEK | 4.86% |
| 2021 FY | 57.68 Million SEK | -3.84% |
| 2021 Q1 | 11.93 Million SEK | -17.03% |
| 2021 Q3 | 15.82 Million SEK | 18.59% |
| 2020 Q3 | 15.82 Million SEK | -1.52% |
| 2020 Q4 | 14.38 Million SEK | -9.08% |
| 2020 FY | 59.99 Million SEK | 4.75% |
| 2020 Q1 | 13.88 Million SEK | 0.83% |
| 2020 Q2 | 16.06 Million SEK | 15.71% |
| 2019 Q4 | 13.77 Million SEK | -22.3% |
| 2019 Q3 | 17.72 Million SEK | 39.9% |
| 2019 FY | 57.27 Million SEK | 17.3% |
| 2019 Q1 | 13.1 Million SEK | -14.57% |
| 2019 Q2 | 12.66 Million SEK | -3.36% |
| 2018 Q3 | 17.25 Million SEK | 93.42% |
| 2018 Q4 | 15.34 Million SEK | -11.06% |
| 2018 FY | 48.82 Million SEK | -3.45% |
| 2018 Q2 | 8.92 Million SEK | 22.09% |
| 2018 Q1 | 7.3 Million SEK | -58.31% |
| 2017 Q4 | 17.52 Million SEK | 48.3% |
| 2017 FY | 50.57 Million SEK | 6.67% |
| 2017 Q1 | 9.67 Million SEK | -4.16% |
| 2017 Q2 | 10.98 Million SEK | 13.49% |
| 2017 Q3 | 11.81 Million SEK | 7.62% |
| 2016 Q1 | 9.22 Million SEK | 4.78% |
| 2016 FY | 47.4 Million SEK | 41.2% |
| 2016 Q4 | 10.09 Million SEK | -34.73% |
| 2016 Q3 | 15.46 Million SEK | 30.01% |
| 2016 Q2 | 11.89 Million SEK | 28.98% |
| 2015 Q1 | 3 Million SEK | -60.14% |
| 2015 Q4 | 8.8 Million SEK | -21.65% |
| 2015 Q2 | 10.37 Million SEK | 245.16% |
| 2015 Q3 | 11.23 Million SEK | 8.27% |
| 2015 FY | 33.57 Million SEK | 1.98% |
| 2014 FY | 32.92 Million SEK | -14.93% |
| 2014 Q4 | 7.54 Million SEK | -25.9% |
| 2014 Q2 | 9.8 Million SEK | 81.48% |
| 2014 Q1 | 5.4 Million SEK | -33.02% |
| 2014 Q3 | 10.18 Million SEK | 3.88% |
| 2013 Q4 | 8.06 Million SEK | -32.81% |
| 2013 FY | 38.69 Million SEK | -2.85% |
| 2013 Q1 | 8.86 Million SEK | -38.82% |
| 2013 Q2 | 9.77 Million SEK | 10.35% |
| 2013 Q3 | 11.99 Million SEK | 22.7% |
| 2012 Q4 | 14.48 Million SEK | 72.43% |
| 2012 Q3 | 8.4 Million SEK | 0.0% |
| 2012 FY | 39.83 Million SEK | 10.71% |
| 2011 FY | 35.97 Million SEK | 24.35% |
| 2010 FY | 28.93 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | -868.258% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 95.599% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 95.599% |
| Arcoma AB | 163.01 Million SEK | 62.93% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | 70.376% |
| BICO Group AB (publ) | 2.23 Billion SEK | 97.302% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | 89.423% |
| CellaVision AB (publ) | 677.29 Million SEK | 91.078% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | -630.436% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | -6089.714% |
| C-Rad AB (publ) | 424.61 Million SEK | 85.769% |
| Duearity AB (publ) | 1.65 Million SEK | -3553.507% |
| Dignitana AB (publ) | 86.06 Million SEK | 29.785% |
| Episurf Medical AB (publ) | 10.3 Million SEK | -486.689% |
| Getinge AB (publ) | 31.82 Billion SEK | 99.81% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | -753.723% |
| Integrum AB (publ) | 104.11 Million SEK | 41.961% |
| Luxbright AB (publ) | 854.69 Thousand SEK | -6970.208% |
| Mentice AB (publ) | 273.61 Million SEK | 77.914% |
| OssDsign AB (publ) | 112.15 Million SEK | 46.121% |
| Paxman AB (publ) | 210.11 Million SEK | 71.24% |
| Promimic AB (publ) | 37.07 Million SEK | -63.013% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -24665.984% |
| SciBase Holding AB (publ) | 23.24 Million SEK | -159.966% |
| Sectra AB (publ) | 2.96 Billion SEK | 97.961% |
| Sedana Medical AB (publ) | 153.86 Million SEK | 60.726% |
| Senzime AB (publ) | 35.75 Million SEK | -69.013% |
| SpectraCure AB (publ) | 318 Thousand SEK | -18902.83% |
| Stille AB | 294.89 Million SEK | 79.508% |
| Vitrolife AB (publ) | 3.51 Billion SEK | 98.279% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | 89.887% |